- Home
- MAX vs IMMX Comparison
MAX vs IMMX Comparison
Compare MAX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | IMMX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.6M | 629.3M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAX | IMMX |
|---|---|---|
| Price | $13.50 | $10.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $12.70 | ★ $19.20 |
| AVG Volume (30 Days) | 754.9K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | $63.95 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $1.94 |
| 52 Week High | $13.92 | $11.61 |
Technical Indicators
Market Signals| Indicator | MAX | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 86.49 | 61.35 |
| Support Level | $12.60 | $7.99 |
| Resistance Level | $13.89 | $10.40 |
| Average True Range (ATR) | 0.62 | 0.78 |
| MACD | 0.34 | 0.16 |
| Stochastic Oscillator | 96.19 | 83.64 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.